What smart money is saying about TG Therapeutics
TGTX
No fund has written a full thesis on TG Therapeutics in our archive, but 1 fund letter reports a position in it — most recently ClearBridge Investments SMID Cap Growth Strategy in June 2026.
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in TG Therapeutics on record in the archive was reported in Q2 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
Fund activity · 1 position
- June 2026
“TG Therapeutics, a commercial-stage biopharmaceutical company focused on therapies for multiple sclerosis, contributed following greater than anticipated growth for its key drug, Briumvi, as well as positive clinical data for a subcutaneous version of the therapy that could expand its addressable market.”
Read the letterTG Therapeutics
Read the letters behind these TG Therapeutics positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger